Overview

Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia

Phase:

Phase 3

Details

Lead Sponsor:

Solvay Pharmaceuticals

Treatments:

Fenofibrate
Metformin